Search Results - "Junius, S."

Rectal plasmablastic lymphoma in Ebstein Barr virus positive and human immunodeficiency virus negative subject after external radiation therapy for prostatic cancer by Bricman, L, Yengue, P, Miscu, C, Junius, S, Waignein, F, Vandenbulcke, J-M

“…Plasmablastic lymphoma (PBL) represents a rare and aggressive subtype of diffuse large B cells lymphoma (DLBCL) most associated with the human immunodeficiency…”
Get more information

Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial by Fonteyne, Valérie, Dirix, P., Van Praet, C., Berghen, C., Albersen, M., Junius, S., Liefhooghe, N., Noé, L., De Meerleer, G., Ost, P., Villeirs, G., Verbeke, S., De Maeseneer, D., Rammant, E., Verghote, F., Elhaseen, E., De Man, K., Decaestecker, K.

“…Adjuvant external beam radiotherapy after radical cystectomy is well tolerated and results in excellent local control rates in high-risk bladder cancer…”
Get full text

SU‐FF‐T‐147: Intra Fractional Motion in Clinical IMRT Prostate Treatments, Warrants the Use of Faster Treatment Techniques by Van den Heuvel, F, Slagmolen, P, Budiharto, T, Junius, S, Verstraete, J, Oyen, R, Haustermans, K

“…Purpose: To estimate intrafracional motion of the prostate in a routine clinical setting and its impact on margin reduction and treatment time. Method and…”
Get full text

SU‐FF‐T‐133: RapidArcTM: Commissioning and Dose Escalation Possibilities by Crijns, W, Depuydt, T, Defraene, G, Verstraete, J, Haustermans, K, Budiharto, T, Junius, S, Van den Heuvel, F

“…Purpose: This paper reports our experience in commissioning RapidArc™ for use in clinical practice. Additionally, we performed a dose escalation planning study…”
Get full text

Evaluating a decision aid for patients with localized prostate cancer in clinical practice by Isebaert, S, Van Audenhove, C, Haustermans, K, Junius, S, Joniau, S, De Ridder, K, Van Poppel, H

“…The aim of the study was to evaluate the usefulness of a decision aid regarding treatment options for patients with early-stage localized prostate cancer. 50…”
Get more information

Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop by Hua, Yichao, Vella, Gerlanda, Rambow, Florian, Allen, Elizabeth, Antoranz Martinez, Asier, Duhamel, Marie, Takeda, Akira, Jalkanen, Sirpa, Junius, Steffie, Smeets, Ann, Nittner, David, Dimmeler, Stefanie, Hehlgans, Thomas, Liston, Adrian, Bosisio, Francesca Maria, Floris, Giuseppe, Laoui, Damya, Hollmén, Maija, Lambrechts, Diether, Merchiers, Pascal, Marine, Jean-Christophe, Schlenner, Susan, Bergers, Gabriele

“…The lack of T cell infiltrates is a major obstacle to effective immunotherapy in cancer. Conversely, the formation of tumor-associated tertiary-lymphoid-like…”
Get full text

60 GENEPI-ENTB 2: an infrastructure for the individualisation of radiotherapy by Junius, S, Haustermans, K, Heeren, G, Fredriksson, M, Chimfwembe, E, Baumann, M, Hoelscher, T, De Ruysscher, D, Grégoire, V

Get full text

7000 A multi-institutional analysis comparing adjuvant and salvage postoperative radiation therapy for prostate cancer patients with undetectable PSA and high-risk features in the prostatectomy specimen by Budiharto, T, Perneel, C, Haustermans, K, Junius, S, Tombal, B, Scalliet, P, Vekemans, K, Joniau, S, Van Poppel, H

Get full text

PD-0850 Adjuvant radiotherapy after cystectomy for patients with bladder cancer: a phase II trial by Fonteyne, V., Dirix, P., Van Praet, C., Berghen, C., Albersen, M., Junius, S., Liefhooghe, N., Noé, L., De Meerleer, G., Ost, P., Decaestecker, K.

Get full text

T2EVOLVE: STANDARDIZATION OF PRE-CLINICAL AND CLINICAL DEVELOPMENT OF ENGINEERED T CELL THERAPY IN EUROPE; A CROSS FUNCTIONAL MULTI STAKEHOLDER INITIATIVE by Luu, M., Sanges, C., Dreuillet, C., Pennings, E., Casucci, M., Franz, P., Donnadieu, E., Quintarelli, C., Guedan, S., Kersten, M., Morris, E., Ivics, Z., Jager, U., Busch, D.H., Gonzalez, E., Paiva, B., Schröder, B., Chu, L., Cabrizo, Y., Ammar, D., Junius, S., Philippar, U., Fleischer, A., Awigena-Cook, J., Schapitz, I., Henderson, D., Kremer, A., Wagers, S., Choudhary, R., Hudecek, M.

“…T2EVOLVE is a breakthrough alliance of academic and industry leaders in cancer immunotherapy that started in 2021, under the European Union's Innovative…”
Get full text

EP-1369: Cystectomy with adjuvant radiotherapy for invasive bladder tumors: early results of a phase II study by Swimberghe, M., Rammant, E., Decaestecker, K., Ost, P., Junius, S., Dirix, P., De Meerleer, G., Fonteyne, V.

Get full text

Feebly-interacting particles: FIPs 2022Workshop Report by Carenza, Pierluca, Milstead, David A., Wallisch, Benjamin

“…Particle physics today faces the challenge of explaining the mystery of dark matter, the origin of matter over anti-matter in the Universe, the origin of the…”
Get full text

Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer by Salgado, Roberto, Junius, Sara, Benoy, Ina, Van Dam, Peter, Vermeulen, Peter, Van Marck, Eric, Huget, Philippe, Dirix, Luc Y.

“…Interleukin‐6 (IL‐6) is a multifunctional cytokine produced by macrophages, T cells, B cells, endothelial cells and tumour cells. Interleukin‐6 is able to…”
Get full text

948 USE OF A DECISION AID REGARDING TREATMENT OPTIONS FOR EARLY PROSTATE CANCER: A SINGLE-INSTITUTIONAL REPORT ON PATTERN OF TREATMENT CHOICE IN 230 PATIENTS by Junius, S, Van Audenhove, C, Haustermans, K, Joniau, S, Ameye, F, Van Poppel, H

Get full text

127 The development and evaluation of a decision aid in the treatment of patients with localized prostate cancer by Isebaert, S., Van Audenhove, C., Van Poppel, H., Junius, S., Joniau, S., De Ridder, K., Haustermans, K.

Get full text

Feebly Interacting Particles: FIPs 2022 workshop report by Antel, C, Battaglieri, M, Beacham, J, Boehm, C, Buchmüller, O, Calore, F, Carenza, P, Chauhan, B, Cladè, P, Coloma, P, Crivelli, P, Dandoy, V, Darmé, L, Dey, B, Deppisch, F. F, De Roeck, A, Drewes, M, Echenard, B, Flambaum, V. V, Foldenauer, P, Gatti, C, Giannotti, M, Golutvin, A, Gonzalez-Garcia, M. C, Gori, S, Goudzovski, E, Granelli, A, Grote, H, Guellati-Khelifa, S, Hajer, J, Harris, P, Hearty, C, Heuchel, D, Hostert, M, Junius, S, Kahlhoefer, F, Klaric, J, Kling, F, Klose, P, Knolle, J, Kopp, J, Kwon, O, Lantwin, O, Lanfranchi, G, Li, L, Lindner, A, Lopez-Pavon, J, Marocco, J, Martin, J. W, Middleton, S, Milstead, S, Oceano, I, O'Hare, C. A. J, Paoloni, A, Pascoli, S, Petcov, S. T, Pospelov, M, Pöttgen, R, Raggi, M, Ripellino, G, Samsonov, I. B, Sandner, S, Söldner-Rembold, S, Shelton, J, Song, N, Sun, C, Stadnik, Y. V, Tastet, J. L, Toro, N, Tran, N, Trevisani, N, Ulmer, S, Urrea, S, Velghe, B, Wallisch, B, Wong, Y. Y. Y, Zorbilmez, C, Zurek, K

“…Particle physics today faces the challenge of explaining the mystery of dark matter, the origin of matter over anti-matter in the Universe, the origin of the…”
Get full text

Serum IL-6 (sIL-6) predicts overall survival in patients with metastatic breast cancer (MBC) by Junius, S., Benoy, I., Salgado, R., Weytjens, R., Van Dam, P., Huget, P., Lemmens, J., Dirix, L.

Get full text

The Tradition of Virgil. Three Papers on the History and Influence of the Poet by Spaeth, John W.

Get full text